These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2801726)

  • 41. Comparison of membrane adsorber (MA) based purification schemes for the down-stream processing of recombinant h-AT III.
    Reif OW; Freitag R
    Bioseparation; 1994 Dec; 4(6):369-81. PubMed ID: 7765681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes.
    Tyler-Cross R; Sobel M; McAdory LE; Harris RB
    Arch Biochem Biophys; 1996 Oct; 334(2):206-13. PubMed ID: 8900394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of fibronectin on the binding of antithrombin III to immobilized heparin.
    Byun Y; Jacobs HA; Feijen J; Kim SW
    J Biomed Mater Res; 1996 Jan; 30(1):95-100. PubMed ID: 8788110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Isolation and characteristics of antithrombin III from human plasma].
    Markova OA; Kalashnikov VV; Khvatov VB
    Vopr Med Khim; 1987; 33(3):62-6. PubMed ID: 3630019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The interaction of heparin with plasma proteins. Demonstration of different binding sites for antithrombin III complexes and antithrombin III.
    McKay EJ; Laurell CB
    J Lab Clin Med; 1980 Jan; 95(1):69-80. PubMed ID: 7350242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement.
    Francis CW; Pellegrini VD; Harris CM; Marder VJ
    Am J Med; 1989 Sep; 87(3B):61S-66S. PubMed ID: 2478015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Use of Recombinant Antithrombin III in Pediatric and Neonatal ECMO Patients.
    Todd Tzanetos DR; Myers J; Wells T; Stewart D; Fanning JJ; Sullivan JE
    ASAIO J; 2017; 63(1):93-98. PubMed ID: 27861430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.
    Paolucci F; Claviés MC; Donat F; Necciari J
    Clin Pharmacokinet; 2002; 41 Suppl 2():11-8. PubMed ID: 12383040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and characterization of recombinant human antithrombin III in Pichia pastoris.
    Mochizuki S; Hamato N; Hirose M; Miyano K; Ohtani W; Kameyama S; Kuwae S; Tokuyama T; Ohi H
    Protein Expr Purif; 2001 Oct; 23(1):55-65. PubMed ID: 11570846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombin III deficiency: clinical relevance and replacement therapy.
    Gallus AS
    Dev Biol Stand; 1987; 67():59-66. PubMed ID: 3609485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
    Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Some immunological investigations on antithrombin III 'Budapest'.
    Lane JL
    Br J Haematol; 1978 Nov; 40(3):459-70. PubMed ID: 107959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome.
    Vaziri ND; Paule P; Toohey J; Hung E; Alikhani S; Darwish R; Pahl MV
    Arch Intern Med; 1984 Sep; 144(9):1802-3. PubMed ID: 6477000
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The plasma turnover of transfused antithrombin concentrate in patients with acquired antithrombin deficiency.
    Harper PL; Park GR; Carrell RW
    Transfus Med; 1996 Mar; 6(1):45-50. PubMed ID: 8696447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy.
    Tyler-Cross R; Sobel M; Marques D; Harris RB
    Protein Sci; 1994 Apr; 3(4):620-7. PubMed ID: 8003980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategy for Cardiovascular Surgery in Patients with Antithrombin III Deficiency.
    Nishimura Y; Takagi Y
    Ann Thorac Cardiovasc Surg; 2018 Aug; 24(4):187-192. PubMed ID: 29681597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capillary affinity chromatography and affinity capillary electrophoresis of heparin binding proteins.
    Wu X; Linhardt RJ
    Electrophoresis; 1998 Nov; 19(15):2650-3. PubMed ID: 9848674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Energetics of hydrogen bond switch, residue burial and cavity analysis reveals molecular basis of improved heparin binding to antithrombin.
    Singh P; Singh K; Jairajpuri MA
    J Biomol Struct Dyn; 2011 Oct; 29(2):339-50. PubMed ID: 21875153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thermodynamic analysis of heparin binding to human antithrombin.
    DeLauder S; Schwarz FP; Williams JC; Atha DH
    Biochim Biophys Acta; 1992 Sep; 1159(2):141-9. PubMed ID: 1390919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.